YOU are your first advocate. Don’t be afraid to ask your healthcare team questions to make sure you’re doing everything you can to help reduce your risk of HER2+ breast cancer recurrence. Talk to your doctor today and take a stand against HER2+ breast cancer recurrence with NERLYNX. NERLYNX is an oral medication taken for 1-year after trastuzumab-based therapy that may help to reduce your risk of HER2+ breast cancer.
NERLYNX can cause side effects, including diarrhea which can be serious.
Please see Important Safety Information: https://nerlynx.com/
Patient Information: https://nerlynx.com/pdf/nerlynx_product_information_download.pdf